178 related articles for article (PubMed ID: 37354155)
21. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
[TBL] [Abstract][Full Text] [Related]
22. The Clinical Prognosis of Presence and Location of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Imaging in Patients with Hypertrophic Cardiomyopathy: a Single-Center Cohort Study.
Li X; Lai L; Luo R; Yang H; Ma H; Yang Z; Zhao S; Su W; Hua W
J Cardiovasc Transl Res; 2021 Oct; 14(5):1001-1016. PubMed ID: 33629154
[TBL] [Abstract][Full Text] [Related]
23. [Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].
Li WX; Liu LW; Wang J; Zuo L; Yang F; Kang N; Lei CH
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1033-1038. PubMed ID: 29325362
[No Abstract] [Full Text] [Related]
24. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
Rubinshtein R; Glockner JF; Ommen SR; Araoz PA; Ackerman MJ; Sorajja P; Bos JM; Tajik AJ; Valeti US; Nishimura RA; Gersh BJ
Circ Heart Fail; 2010 Jan; 3(1):51-8. PubMed ID: 19850699
[TBL] [Abstract][Full Text] [Related]
25. Texture signatures of native myocardial T
Neisius U; El-Rewaidy H; Kucukseymen S; Tsao CW; Mancio J; Nakamori S; Manning WJ; Nezafat R
J Magn Reson Imaging; 2020 Sep; 52(3):906-919. PubMed ID: 31971296
[TBL] [Abstract][Full Text] [Related]
26. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy.
Ismail TF; Jabbour A; Gulati A; Mallorie A; Raza S; Cowling TE; Das B; Khwaja J; Alpendurada FD; Wage R; Roughton M; McKenna WJ; Moon JC; Varnava A; Shakespeare C; Cowie MR; Cook SA; Elliott P; O'Hanlon R; Pennell DJ; Prasad SK
Heart; 2014 Dec; 100(23):1851-8. PubMed ID: 24966307
[TBL] [Abstract][Full Text] [Related]
27. [The value of cardiac MRI in the risk stratification in patients with hypertrophic cardiomyopathy].
Wang JX; Yang SJ; Ma X; Yu SQ; Dong ZX; Xiang XR; Wei ZX; Cui C; Yang K; Chen XY; Lu MJ; Zhao SH
Zhonghua Xin Xue Guan Bing Za Zhi; 2023 Jun; 51(6):619-625. PubMed ID: 37312480
[No Abstract] [Full Text] [Related]
28. Late gadolinium enhancement is common in patients with hypertrophic cardiomyopathy and no clinical risk factors for sudden cardiac death: A single center experience.
Lyons KS; Dixon LJ; Johnston N; Noad R; Hamilton A; McKeag N; Horan P
Cardiol J; 2014; 21(1):29-32. PubMed ID: 23990187
[TBL] [Abstract][Full Text] [Related]
29. The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast-enhanced magnetic resonance study.
Weissler-Snir A; Hindieh W; Spears DA; Adler A; Rakowski H; Chan RH
J Cardiovasc Electrophysiol; 2019 May; 30(5):651-657. PubMed ID: 30680853
[TBL] [Abstract][Full Text] [Related]
30. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study.
Rowin EJ; Maron MS; Adler A; Albano AJ; Varnava AM; Spears D; Marsy D; Heitner SB; Cohen E; Leong KMW; Winters SL; Martinez MW; Koethe BC; Rakowski H; Maron BJ
Heart Rhythm; 2022 May; 19(5):782-789. PubMed ID: 34933112
[TBL] [Abstract][Full Text] [Related]
31. Incremental benefit of late gadolinium cardiac magnetic resonance imaging for risk stratification in patients with hypertrophic cardiomyopathy.
Doesch C; Tülümen E; Akin I; Rudic B; Kuschyk J; El-Battrawy I; Becher T; Budjan J; Smakic A; Schoenberg SO; Borggrefe M; Papavassiliu T
Sci Rep; 2017 Jul; 7(1):6336. PubMed ID: 28740148
[TBL] [Abstract][Full Text] [Related]
32. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.
Avanesov M; Münch J; Weinrich J; Well L; Säring D; Stehning C; Tahir E; Bohnen S; Radunski UK; Muellerleile K; Adam G; Patten M; Lund G
Eur Radiol; 2017 Dec; 27(12):5136-5145. PubMed ID: 28616729
[TBL] [Abstract][Full Text] [Related]
33. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.
Maron MS; Rowin EJ; Wessler BS; Mooney PJ; Fatima A; Patel P; Koethe BC; Romashko M; Link MS; Maron BJ
JAMA Cardiol; 2019 Jul; 4(7):644-657. PubMed ID: 31116360
[TBL] [Abstract][Full Text] [Related]
34. Validation of the Risk Stratification for Sudden Cardiac Death in Chinese Patients With Hypertrophic Cardiomyopathy.
Qi W; Pu L; Zhang J; Chen H; Tang Z; Wang J; Han Y; Chen Y
Curr Probl Cardiol; 2023 Nov; 48(11):101875. PubMed ID: 37331610
[TBL] [Abstract][Full Text] [Related]
35. Supplementary role of left ventricular global longitudinal strain for predicting sudden cardiac death in hypertrophic cardiomyopathy.
Lee HJ; Kim HK; Lee SC; Kim J; Park JB; Hwang IC; Choi YJ; Lee SP; Chang SA; Lee W; Park EA; Cho GY; Kim YJ
Eur Heart J Cardiovasc Imaging; 2022 Jul; 23(8):1108-1116. PubMed ID: 34542591
[TBL] [Abstract][Full Text] [Related]
36. Radiomics and deep learning for myocardial scar screening in hypertrophic cardiomyopathy.
Fahmy AS; Rowin EJ; Arafati A; Al-Otaibi T; Maron MS; Nezafat R
J Cardiovasc Magn Reson; 2022 Jun; 24(1):40. PubMed ID: 35761339
[TBL] [Abstract][Full Text] [Related]
37. Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function.
Mentias A; Raeisi-Giglou P; Smedira NG; Feng K; Sato K; Wazni O; Kanj M; Flamm SD; Thamilarasan M; Popovic ZB; Lever HM; Desai MY
J Am Coll Cardiol; 2018 Aug; 72(8):857-870. PubMed ID: 30115224
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Role of the Progression of Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy.
Aquaro GD; Todiere G; Barison A; Grigoratos C; Parisella ML; Adami M; Grilli G; Pagura L; Faggioni L; Cioni D; Lencioni R; Emdin M; Neri E
Am J Cardiol; 2024 Jan; 211():199-208. PubMed ID: 37949342
[TBL] [Abstract][Full Text] [Related]
39. Cardiac MRI Risk Stratification for Dilated Cardiomyopathy with Left Ventricular Ejection Fraction of 35% or Higher.
Li S; Wang Y; Yang W; Zhou D; Zhuang B; Xu J; He J; Yin G; Fan X; Wu W; Sharma P; Sirajuddin A; Arai AE; Zhao S; Lu M
Radiology; 2023 Mar; 306(3):e213059. PubMed ID: 36318031
[TBL] [Abstract][Full Text] [Related]
40. Early Repolarization Pattern and Left Ventricular Mass in Hypertrophic Cardiomyopathy.
Azevedo PMO; Guerreiro C; Ladeiras-Lopes R; Ferreira N; Faria R; Barbosa R; Primo J; Braga J
Cardiology; 2020; 145(5):303-308. PubMed ID: 32018270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
